HPV testing is a medical screening procedure used to detect Human Papillomavirus (HPV) infection, primarily targeting high-risk types that may lead to cervical and related cancers. This test analyzes DNA from cervical or mucosal cells to determine if specific oncogenic HPV types are present, thereby assessing cancer risk. Its main goal is to detect potential lesions early; combined with other diagnostic procedures, it can effectively reduce cervical cancer mortality.
This test is often used in conjunction with Pap smear tests, forming a dual screening system. Especially for women over 30, medical guidelines recommend HPV testing every 3 to 5 years to improve the detection rate of precancerous lesions. Positive results require further examination via colposcopy or biopsy to confirm if treatment is necessary.
HPV testing mainly falls into two categories: "DNA sequencing methods" and "automated molecular diagnostic techniques." DNA sequencing involves amplifying viral DNA fragments via PCR (Polymerase Chain Reaction) and comparing them to known oncogenic types (such as types 16 and 18). Automated techniques utilize biochips or chemiluminescence methods for rapid screening of high-risk HPV types.
The mechanism involves directly detecting the presence of viral genes rather than merely observing cellular abnormalities. Compared to traditional Pap smears, HPV testing can detect persistent infections earlier, even before cells show significant lesions, thus predicting future cancer risk. The sensitivity of this technology exceeds 90%, especially valuable for patients over 30.
Primarily suitable for women over 30 for routine cervical cancer screening, and for those with inconclusive Pap smear results (such as ASC-US). Additionally, women who have undergone LEEP procedures, immunocompromised patients, or those with a family history of cervical cancer should undergo regular testing. Some countries include it as part of routine screening for women over 25.
In complex cases, HPV testing can serve as a second-line tool. For example, when Pap results are normal but vaginal bleeding persists, or when patients refuse biopsy, HPV testing can provide additional diagnostic information. However, it should be noted that this test is not suitable during active acute reproductive tract infections.
The sample collection is usually performed simultaneously with a Pap smear. The physician uses a specialized spatula to collect cells from the transformation zone of the cervix, placing them into a special preservation solution for laboratory analysis. No special preparation is needed, but it is recommended to perform the test 3 to 7 days after menstruation to reduce blood interference. The entire process takes about 5 to 10 minutes, with results available in 3 to 7 working days.
Special populations, such as women who have had a hysterectomy, should confirm with their doctor whether testing is necessary. If the results are positive for HPV types 16 or 18, immediate colposcopy is required regardless of cytology results. For non-high-risk types, follow-up plans are based on risk stratification.
The non-invasive nature of the test results in high patient acceptance, and a single test can analyze multiple high-risk types simultaneously. The development of digital automated analysis systems further shortens reporting times and improves medical efficiency.
The test itself carries no biological risks but may produce "false-positive" results, causing psychological stress and unnecessary follow-up procedures. About 5-10% of positive cases do not develop precancerous lesions, which may lead to anxiety or misdiagnosis.
Contraindications include active acute reproductive tract infections, severe cervical trauma, or bleeding. Patients should avoid sexual activity, vaginal douching, or use of vaginal medications 48 hours before the test to prevent sample contamination. Immunocompromised patients (such as HIV carriers) should have shortened screening intervals.
Results should be interpreted in conjunction with clinical symptoms and age. A positive result alone is not diagnostic of cancer. During pregnancy, if asymptomatic, it is recommended to delay testing until 6 weeks postpartum to avoid procedural risks.
HPV test results are analyzed alongside Pap smear results to form a "combined screening strategy." For example, if both are abnormal, immediate treatment is necessary; if only HPV is positive, enhanced follow-up is required. This technology also complements vaccination programs; even after HPV vaccination, regular screening remains essential, as vaccines cannot eliminate existing infections.
Regarding cancer treatments, positive results may lead to follow-up procedures such as LEEP or cold knife conization. The test results do not conflict with chemotherapy or radiotherapy but should be interpreted with caution during tissue healing post-treatment, which may affect accuracy.
Large clinical trials show that HPV testing alone can reduce cervical cancer mortality by about 70%, with better outcomes when combined with cytology. A Finnish study followed up over 10 years found that among 1,000 screened women, an additional 23 cases of high-grade lesions were detected.
The World Health Organization (WHO) recommends women over 30 undergo HPV testing every 5 years, based on epidemiological data from over 20 countries. The FDA-approved testing kits have an accuracy of 98%, effectively distinguishing transient from persistent infections.
Traditional Pap smear relies on cytological evaluation but has lower sensitivity for early lesions. New liquid-based cytology improves accuracy but cannot directly determine HPV type. Colposcopy remains the gold standard for diagnosis but is invasive and not suitable for routine screening.
PCR gene sequencing can precisely identify HPV types but is costly and time-consuming, typically used for suspected recurrent infections or post-treatment follow-up. Self-sampling kits are emerging options, allowing patients to collect vaginal cells themselves, increasing screening coverage in remote areas.
Mild bleeding or discomfort after treatment is normal and usually subsides within 1-2 weeks. If bleeding exceeds normal periods, persists for more than 7 days, or pain is severe, contact your healthcare provider immediately. The doctor may recommend resting from vigorous activities, avoiding tampons, and may prescribe pain relievers or antibiotics to prevent infection.
Should I adjust my diet or exercise habits during treatment?It is advisable to avoid spicy and irritating foods to reduce inflammation; also, refrain from strenuous activities (such as heavy lifting or running) to minimize trauma or bleeding. Maintain a light diet rich in vitamin C and protein to promote tissue repair. Normal activities can usually resume gradually after two weeks.
What are the differences between LEEP and cold knife conization? How do I choose?LEEP (Loop Electrosurgical Excision Procedure) uses electric current to remove abnormal tissue and is suitable for larger or more widespread lesions, allowing for simultaneous histological examination. Cold knife conization involves excising tissue with a surgical knife and is preferred for deeper or more localized lesions. The choice depends on lesion size, depth, and patient factors; discuss options thoroughly with your doctor before the procedure.
When can I resume sexual activity after treatment? What precautions should I take?It is generally recommended to wait at least 4 weeks post-treatment before resuming sexual activity, allowing the wound to heal completely. Use water-based lubricants to reduce friction and avoid products like douches or vaginal sprays that may cause irritation. If there is ongoing discharge or pain within three weeks post-treatment, delay intercourse and consult your healthcare provider.
How often should follow-up examinations be performed? What are signs of incomplete recovery?Follow-up typically involves HPV testing and Pap smears every 6 months in the first year. If results are normal for two consecutive years, the interval can be extended to every 3 years. Signs of incomplete recovery include persistent foul-smelling discharge, non-menstrual bleeding, post-coital bleeding, or ongoing lower abdominal pain. Seek medical evaluation promptly for further assessment or treatment.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
